Desensitization protocol should not be used in acute lymphoblastic leukemia patients with silent inactivation of PEGasparaginase

Samankaltaisia teoksia

• A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia
  Tekijä: Tong, Wing H., et al.
  Julkaistu: (2014)
• The toxicity of very prolonged courses of PEGasparaginase or Erwinia asparaginase in relation to asparaginase activity, with a special focus on dyslipidemia
  Tekijä: Tong, Wing H., et al.
  Julkaistu: (2014)
• First-line treatment of acute lymphoblastic leukemia with pegasparaginase
  Tekijä: Masetti, Riccardo, et al.
  Julkaistu: (2009)
• Pediatric Acute Lymphoblastic Leukemia: Efficacy and safety of recombinant E. coli-asparaginase in infants (less than one year of age) with acute lymphoblastic leukemia
  Tekijä: van der Sluis, Inge, et al.
  Julkaistu: (2013)
• Individualized dosing guidelines for PEGasparaginase and factors influencing the clearance: a population pharmacokinetic model
  Tekijä: Kloos, Robin Q.H., et al.
  Julkaistu: (2020)